L. Z. Afandieva

L. Z. Afandieva

Auto-generated profile, based on publicly available information

L. Z. Afandieva

Kazan State Medical University, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
Verified
Journal Article
Open access
PDF file
DGD. D. Gainetdinova
D. D. Gainetdinova
LAL. Z. Afandieva
L. Z. Afandieva
RHR. F. Hakimova
R. F. Hakimova
Особенности иммунологических показателей у детей раннего возраста, больных спастическими формами детского церебрального паралича

24 May 2024 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
LAL. Z. Afandieva
L. Z. Afandieva
DGD. D. Gaynetdinova
D. D. Gaynetdinova
DID. V. I
D. V. I
Pathogenetic nucleotide variants at many genetic loci can cause conditions like cerebral palsy. Establishing the etiologic diagnosis is clinically important for optimal disease management and treatment.The presented family case demonstrates a clinical polymorphism associated with variants in the EBF3 gene that impaired transcription regulation. The described variant c.703CT (p.His235Tyr) in the EBF3 leads to severe motor and intellectual disability mimicking cerebral palsy.Timely detection of monogenic diseases hiding under the mask of cerebral palsy will help to establish a timely diagnosis and conduct medical and genetic counseling to prevent recurrent cases in the family.

19 June 2026 in Neuromuscular Diseases
Verified
Journal Article
Closed access
PDF file
DGD. D. Gaynetdinova
D. D. Gaynetdinova
ГДГайнетдинова Д. Д.
Гайнетдинова Д. Д.
AYA. Sh. Yuldashev
A. Sh. Yuldashev
ЮШЮлдашев А. Ш.
Юлдашев А. Ш.
LAL. Z. Afandieva
L. Z. Afandieva
АЗАфандиева Л. З.
Афандиева Л. З.
The relevance of this work is determined by the fact that comorbid disorders in children with cerebral palsy – such as pain, cognitive impairment, epilepsy, dysphagia, sensory deficits and other associated conditions – shape a complex clinical profile already in early childhood. These conditions, rather than motor impairment alone, become key barriers to effective rehabilitation, social participation and maintenance of an acceptable quality of life. Despite advances in rehabilitation medicine, delayed recognition and management of comorbidities remain a major cause of persistent disability, underscoring the need to systematically summarize current evidence. The present analysis not only describes the characteristics of the most frequent comorbid conditions, but also identifies several key patterns. Pain in children with cerebral palsy is shown to be polymorphic and frequently chronic, and its assessment in early childhood requires the use of specialized scales. A clear relationship is demonstrated between the severity of motor impairment and the risk of cognitive decline, along with a high prevalence of speech disorders, among which dysarthria predominates. Particular attention is given to epilepsy and dysphagia, which directly threaten survival through malnutrition and respiratory complications. The main value of this review lies in the critical synthesis of data on diagnostic approaches adapted for infants, nonverbal children and those with severe motor limitations, as well as in the discussion of how comorbidity shapes the clinical course of cerebral palsy and why the focus must shift towards the earliest possible multidisciplinary management, starting from the time of diagnosis, in order to preserve rehabilitation potential and improve quality of life in this vulnerable population.

5 June 2026 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
DGD.D. Gaynetdinova
D.D. Gaynetdinova
LAL.Z. Afandieva
L.Z. Afandieva
Objective. To evaluate the ability of ethylmethylhydroxypyridine succinate (Mexidol) to modulate free radical oxidation rates and pro-inflammatory cytokine activity as a part of comprehensive medical rehabilitation for children diagnosed with spastic cerebral palsy. Material and methods. The study cohort included children aged 6 to 8 years with spastic cerebral palsy (CP). Group 1 (n=24) received Mexidol in combination with robotic therapy incorporating biofeedback for 6 weeks. Group 2 (n=23) received only robotic therapy. Assessments were conducted on free radical oxidation indicators, serum levels of pro-inflammatory cytokines (tumor necrosis factor α [TNF-α] and interleukin-6 [IL-6]), and functional cognitive and motor indicators, utilizing data obtained from the integrated sensors of the exoskeleton platform. Results. In children with spastic forms of cerebral palsy, two concurrent pathogenetic processes were observed: systemic inflammation, indicated by elevated levels of TNF-α and IL-6, and oxidative stress, marked by increased activity of antioxidant defense enzymes (peroxidase, catalase, and superoxide dismutase) alongside indicators of lipid peroxidation (malondialdehyde). The complex therapy demonstrated a statistically significant advantage in improving motor and cognitive indicators compared to robotic therapy only. Specifically, improvements in motor indicators ranged from 37.6% to 58.7%, while cognitive improvements ranged from 14.4% to 52.6%. These enhancements were found to significantly exceed those observed in the group receiving only robotic therapy (motor improvements of 24% to 39% and cognitive improvements of 5% to 22%; intergroup differences p<0.05). Conclusion. The combination therapy in children with spastic cerebral palsy effectively enhances both motor and cognitive functions while modulating antioxidant status and systemic inflammation. The integration of antioxidant pharmacotherapy into rehabilitation programs has been shown to increase the efficacy of training, thereby facilitating the development of a biomarker-driven approach to personalized treatment.